ATTENTION GENERAL and FAMILY/PARENTING Contacts…
Inc
D S Simon Productions
212.736.2727
Hope for 14 Million+ Rosacea Sufferers
48-Week Clinical Study of Pyratine XRTM Shows
Significant Reductions of All Three Major Symptoms of Rosacea
April is Rosacea Awareness Month
Key study findings:
 Significant reductions of redness (erythema): A decrease in redness of 22.2% was reported at week 12 and
progressed to a 44.5% reduction by week 36.
 Significant reduction of lesions (papules and pustules): A reduction of 21% in lesion count was reported as soon as
week four and improved to an 89.5% decrease at week 48.
 Significant reductions in spider veins (telangiectasia): A reduction of 12% was recorded as soon as week four and
progressed to a 27.8% decrease by week 36.
(Source: controlled clinical trials conducted at University of California, Irvine)
Story description:
According to the National Rosacea Society, there are more than 14 million people in the United States with rosacea, yet only
a small number are being treated. Rosacea is a chronic condition that often requires extended treatment periods which often
cause side effects, and treatments that provide sustained relief of the signs and symptoms of rosacea are needed. Current
topical agents can cause high skin sensitivity and oral antibiotics are not suitable for continuous long-term use due to
concerns about thier affect on healthy intestinal bacteria.
A new cosmesecutical, Pyratine XR, may offer them hope. A recent study conducted at the University of California, Irvine, of
mild to moderate rosacea patients found that Pyratine XR – a non-prescription, physician-dispensed product – showed
improvement for all of the major signs and symptoms of rosacea. The study findings were just presented at both the
American Academy of Dermatology’s annual meeting and the South Beach Clinical Dermatology Symposium.
After the 48-week clinical trial, there was an overall clinical improvement in 80% of subjects. The investigators saw continual,
statistically significant mean improvement, including a 90% improvement in lesions, 45% improvement in erythema (redness)
and a 28% improvement in telangiectasia (spider veins). As early as week 4, there was significant improvement in skin
barrier function, decrease of water loss, and a 41% mean improvement in skin dryness. The product was well tolerated by all
subjects.
This B-roll and Soundbites Include:
 Interview with leading dermatologist Dr. Mark Nestor, who presented the study at the South Beach Clinical Dermatology
Symposium, speaking to rosacea in general and the study results
 Interview with Frank Massino, Chief Executive Officer & Chairman, Senetek PLC, the R&D company that developed
Pyratine XR
 Footage of a rosacea patient being examined and diagnosed (consultation, skin imaging, etc)
 Pyratine XR manufacturing footage
 Exteriors of American Academy of Dermatology conference meetings
All footage is available for coverage during Rosacea Awareness Month (April) and beyond.
To view this video, obtain a copy of the alert or script, or request a hard copy tape, please go to:
www.media.dssimon.com/taperequest/mr1.php
Station Note: This video is for your free and unrestricted use. Funding has been provided by Senetek.
Satellite Feed Information:
Date: Tuesday, March 31st, 2009
Times: 1:30 PM- 1:45 PM Eastern
12:30 PM- 12:45 PM Central
11:30 AM- 11:45AM Mountain
10:30 AM- 11:45AM Pacific
C-Band Satellite: 3C
Transponder: 4C
Downlink: 3780 (V) Audio: 6.2 & 6.8
Date: Thursday, April 2nd, 2009
Times: 1:30PM- 1:45PM Eastern
12:30PM- 12:45PM Central
11:30AM- 11:45AM Mountain
10:30AM- 10:45AM Pacific
C-Band Satellite: 3C
Transponder: 8C
Downlink: 3860 (V) Audio:6.2&6.8
For More Information, Contact D S Simon Productions Inc:
Media Relations Department: John Hanrahan / Brian Devenny / Jovanna David
ATTENTION MEDICAL & GENERAL REPORTERS …
Phone: 212.736.2727 or 1.800.DSSimon
E-mail: johnh@dssimon.com, briand@dssimon.com, jovannad@dssimon.com
If you do not wish to receive faxes, please call 1.800.DSSIMON and we will remove you from our list.
D S Simon Productions Inc
212.736.2727